Immediate Impact
25 hit
Citing Papers
Strategic advancements in targeting the PI3K/AKT/mTOR pathway for Breast cancer therapy
2025 Hit
Next-generation agentic AI for transforming healthcare
2025 Hit
Works of Sarah Kernaghan being referenced
Assessment of structural chromosomal instability phenotypes as biomarkers of carboplatin response in triple negative breast cancer: the TNT trial
2020
Abstract OT1-06-03: The plasmaMATCH trial: A multiple parallel cohort, open-label, multi-centre phase II clinical trial of ctDNA screening to direct targeted therapies in patients with advanced breast cancer (CRUK/15/010)
2018
Author Peers
| Author | Last Decade | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|
| Sarah Kernaghan | 34 | 29 | 23 | 11 | 7 | 10 | 52 | |
| José Rodrigo Espinosa Fernández | 43 | 24 | 10 | 16 | 6 | 9 | 66 | |
| Swapnil Parmar | 43 | 22 | 30 | 20 | 1 | 10 | 71 | |
| Yiu-Keung Lau | 29 | 9 | 20 | 6 | 2 | 10 | 54 | |
| Anna Maria Lavecchia | 23 | 27 | 8 | 19 | 4 | 11 | 64 | |
| Richard Packer | 25 | 16 | 21 | 24 | 3 | 9 | 75 | |
| Geoffrey Fell | 19 | 21 | 13 | 22 | 2 | 10 | 68 | |
| Seri Park | 30 | 23 | 13 | 11 | 1 | 10 | 50 | |
| Samira Bensfia | 53 | 27 | 14 | 12 | 1 | 9 | 65 | |
| Sébastien Armanet | 26 | 44 | 21 | 21 | 8 | 65 | ||
| Samuel M. Niman | 55 | 39 | 23 | 15 | 14 | 74 |
All Works
Loading papers...